Host Receptor Targeting to Treat Covid-19.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38320534.
- Also identified by DOI 10.1056/EVIDe2300222.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Not long after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of coronavirus disease 2019 (Covid-19), in vitro experiments revealed that SARS-CoV-2 infection of human cells depended on the binding of the viral spike protein to the human cell-surface receptor angiotensin-converting enzyme 2 (ACE-2).<sup>1</sup> Additional experiments demonstrated that infection could be blocked by inhibiting transmembrane protease, serine 2 (TMPRSS2), which is a host enzyme that cleaves the viral spike protein after binding to ACE-2 and facilitates entry of the virus into the host cell.
Medical subject headings
- COVID-19